The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

NCT02493582 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of Lung

Interventions

BIOLOGICAL: Cytokine-Induced Killer Cells
DRUG: Apatinib

Sponsor

The First People's Hospital of Changzhou